Fibronectin modulates endothelial response to HIV type 1 Tat. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Fibronectin modulates endothelial response to HIV type 1 Tat.

AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1341-8. Unique Identifier : AIDSLINE MED/97479770
Cavallaro U; Mariotti M; Wu ZH; Soria MR; Maier JA; Department of Biological and Technological Research, San Raffaele; Institute, Milan, Italy.

Abstract: The normal function of the endothelium is impaired in HIV-1 infection. Disturbances of the local cytokines as well as the release of HIV-1 Tat by infected mononuclear cells play a role in endothelial dysfunction. We studied the effects of Tat on the human endothelial ECV cell line. In this system, Tat inhibited cell proliferation only in the presence of fibronectin as a culture substrate, whereas it did not modulate plasminogen activator activity, cell migration, or synthesis of fibronectin. Because amino acids 49-57 contains a nuclear translocation sequence, we also evaluated the potential intracellular role of Tat in tat-transfected ECV cells. tat transfectants showed inhibition of cell growth, unaffected cell migration and plasminogen activator activity, and a significant induction of the expression of fibronectin.
Keywords: Blotting, Western Cell Division/GENETICS Cell Movement/GENETICS Cells, Cultured Endothelium/CYTOLOGY/*METABOLISM/VIROLOGY Fibronectins/BIOSYNTHESIS/METABOLISM/*PHARMACOLOGY Fluorescent Antibody Technique, Direct Gene Expression Gene Products, tat/GENETICS/IMMUNOLOGY/*METABOLISM Human HIV Antigens/*METABOLISM HIV Infections/*METABOLISM *HIV-1 Plasminogen Activators/METABOLISM/PHARMACOLOGY Precipitin Tests Recombinant Proteins/METABOLISM Recombination, Genetic Support, Non-U.S. Gov't Transfection JOURNAL ARTICLEKWDblotting,westerncelldivision/geneticscellmovement/geneticscells,culturedendothelium/cytology/KWDmetabolism/virologyfibronectins/biosynthesis/metabolism/KWDpharmacologyfluorescentantibodytechnique,directgeneexpressiongeneproducts,tat/genetics/immunology/KWDmetabolismhumanhivantigens/KWDmetabolismhivinfections/KWDmetabolismKWDhiv-1plasminogenactivators/metabolism/pharmacologyprecipitintestsrecombinantproteins/metabolismrecombination,geneticsupport,non-uKWDsKWDgov'ttransfectionjournalarticle
980228
M9820719

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .